INT76336

From wiki-pain
Revision as of 00:37, 21 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1998
Last Reported 2010
Negated 0
Speculated 3
Reported most in Abstract
Documents 192
Total Number 196
Disease Relevance 112.02
Pain Relevance 20.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (PDE5A) signal transduction (PDE5A) cellular_component (PDE5A)
Anatomy Link Frequency
corpus 8
penis 6
smooth muscle 5
blood 5
nerve 3
PDE5A (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 472 99.96 Very High Very High Very High
sSRI 344 99.74 Very High Very High Very High
headache 345 99.60 Very High Very High Very High
tramadol 64 99.60 Very High Very High Very High
Angina 90 99.56 Very High Very High Very High
Analgesic 19 99.42 Very High Very High Very High
Multiple sclerosis 84 99.26 Very High Very High Very High
Opioid 31 99.22 Very High Very High Very High
nud 149 99.04 Very High Very High Very High
Migraine 24 99.04 Very High Very High Very High
Disease Link Frequency Relevance Heat
Premature Ejaculation 1243 100.00 Very High Very High Very High
Reprotox - General 2 2775 99.92 Very High Very High Very High
Benign Prostatic Hypertrophy 460 99.92 Very High Very High Very High
Cognitive Disorder 253 99.88 Very High Very High Very High
Pulmonary Hypertension 2125 99.84 Very High Very High Very High
Neurodegenerative Disease 222 99.80 Very High Very High Very High
Disease 715 99.68 Very High Very High Very High
Deafness 55 99.64 Very High Very High Very High
Headache 362 99.60 Very High Very High Very High
Neurological Disease 44 99.60 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Vardenafil and sildenafil are potent and specific phosphodiesterase type 5 (PDE 5) inhibitors.
Negative_regulation (inhibitors) of PDE 5
1) Confidence 0.59 Published 2002 Journal J. Androl. Section Abstract Doc Link 12002434 Disease Relevance 0.23 Pain Relevance 0
Sildenafil has no direct relaxant effect on human corpus cavernosum but enhances the relaxant effect of nitric oxide (NO) on the corpus cavernosum by inhibiting PDE5, which is responsible for degradation of cGMP in this tissue.
Negative_regulation (inhibiting) of PDE5 in corpus
2) Confidence 0.59 Published 1998 Journal Clin Ther Section Abstract Doc Link 9916601 Disease Relevance 0.16 Pain Relevance 0.03
Sildenafil citrate, an oral therapy for erectile dysfunction, is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), the predominant isozyme metabolizing cGMP in the corpus cavernosum.
Negative_regulation (inhibitor) of PDE5 in corpus associated with reprotox - general 2
3) Confidence 0.59 Published 1998 Journal Clin Ther Section Abstract Doc Link 9916601 Disease Relevance 0.17 Pain Relevance 0
When sexual stimulation causes local release of NO, inhibition of PDE5 by sildenafil increases concentrations of cGMP in the corpus cavernosum, causing smooth muscle relaxation and blood flow into the penis, resulting in an erection.
Negative_regulation (inhibition) of PDE5 in corpus
4) Confidence 0.59 Published 1998 Journal Clin Ther Section Abstract Doc Link 9916601 Disease Relevance 0.15 Pain Relevance 0.04
M1, an active metabolite of vardenafil, is a four-fold-less potent inhibitor of PDE5 than its parent compound, contributing approximately 7% to vardenafil's overall efficacy.
Negative_regulation (inhibitor) of PDE5
5) Confidence 0.59 Published 2004 Journal Int. J. Impot. Res. Section Abstract Doc Link 15224134 Disease Relevance 0 Pain Relevance 0.21
Vardenafil potently inhibits human phosphodiesterase 5 (PDE5) with an IC50 of 0.7 nM.
Negative_regulation (inhibits) of PDE5
6) Confidence 0.59 Published 2004 Journal Int. J. Impot. Res. Section Abstract Doc Link 15224134 Disease Relevance 0 Pain Relevance 0.10
The treatment of erectile dysfunction (ED) has been revolutionised by new agents to inhibit the enzyme PDE5.
Negative_regulation (inhibit) of PDE5 associated with reprotox - general 2
7) Confidence 0.59 Published 2003 Journal Expert Opin Pharmacother Section Abstract Doc Link 12614192 Disease Relevance 0.36 Pain Relevance 0
With the use of sildenafil, it has been clearly, clinically demonstrated that the selective inhibition of PDE5 is an appropriate, effective, safe method for the treatment of ED of all aetiologies and severities.
Negative_regulation (inhibition) of PDE5 associated with reprotox - general 2
8) Confidence 0.59 Published 2003 Journal Expert Opin Pharmacother Section Abstract Doc Link 12614192 Disease Relevance 0.69 Pain Relevance 0.09
Adverse events are usually associated with the vascular changes from PDE5 inhibition.
Negative_regulation (inhibition) of PDE5
9) Confidence 0.59 Published 2003 Journal Expert Opin Pharmacother Section Abstract Doc Link 12614192 Disease Relevance 0.73 Pain Relevance 0.10
The scientific basis of this treatment of ED includes relaxation of the corpus cavernosum smooth muscle tissue by inhibition of PDE5 that breaks down cGMP, the key pathway for the production of erectile function in humans.
Negative_regulation (inhibition) of PDE5 in smooth muscle tissue associated with reprotox - general 2
10) Confidence 0.59 Published 2003 Journal Expert Opin Pharmacother Section Abstract Doc Link 12614192 Disease Relevance 0.47 Pain Relevance 0
PDE5 inhibitors are available by prescription only and are not for everyone.
Negative_regulation (inhibitors) of PDE5
11) Confidence 0.59 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778425 Disease Relevance 0.44 Pain Relevance 0
Sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5), is a well-tolerated and highly effective treatment for erectile dysfunction.
Negative_regulation (inhibitor) of PDE5 associated with erectile dysfunction
12) Confidence 0.59 Published 1999 Journal Am. J. Cardiol. Section Abstract Doc Link 10078539 Disease Relevance 0.18 Pain Relevance 0.04
Sildenafil is a potent and selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP).
Negative_regulation (inhibitor) of PDE5
13) Confidence 0.59 Published 2000 Journal Am. J. Med. Section Abstract Doc Link 11137498 Disease Relevance 0.36 Pain Relevance 0
Sildenafil (Viagra), a selective inhibitor of phosphodiesterase 5 (PDE5), induces headache and migraine.
Negative_regulation (inhibitor) of phosphodiesterase 5 associated with migraine and headache
14) Confidence 0.59 Published 2005 Journal Eur. J. Pharmacol. Section Abstract Doc Link 16182282 Disease Relevance 0.29 Pain Relevance 0.29
Sildenafil (Viagra), a selective inhibitor of phosphodiesterase 5 (PDE5), induces headache and migraine.
Negative_regulation (inhibitor) of PDE5 associated with migraine and headache
15) Confidence 0.59 Published 2005 Journal Eur. J. Pharmacol. Section Abstract Doc Link 16182282 Disease Relevance 0.29 Pain Relevance 0.29
Inhibition of PDE5 blocks the hydrolysis of cyclic guanosine monophosphate (GMPc) and results in increased arterial blood flow leading to enlargement of the corpus cavernosum and resulting in erection.
Negative_regulation (Inhibition) of PDE5 in corpus
16) Confidence 0.59 Published 2003 Journal Rev Med Liege Section Abstract Doc Link 14626653 Disease Relevance 0.06 Pain Relevance 0
Inhibition of PDE5 results in increased arterial blood flow leading to enlargement of the corpus cavernosum.
Negative_regulation (Inhibition) of PDE5 in corpus
17) Confidence 0.59 Published 2002 Journal Drugs Aging Section Abstract Doc Link 12027779 Disease Relevance 0.11 Pain Relevance 0
Vardenafil selectively inhibits phosphodiesterase type 5 (PDE5), an enzyme which hydrolyses cyclic guanosine monophosphate in the cavernosum tissue of the penis.
Negative_regulation (inhibits) of PDE5 in penis
18) Confidence 0.59 Published 2002 Journal Drugs Aging Section Abstract Doc Link 12027779 Disease Relevance 0 Pain Relevance 0
Sildenafil, which selectively inhibits phosphodiesterase type 5 (PDE5) found predominantly in the corpora cavernosa of the penis, effectively blocks the degradation of cGMP and enhances erectile function in men with erectile dysfunction.
Negative_regulation (inhibits) of PDE5 in penis associated with reprotox - general 2
19) Confidence 0.59 Published 1999 Journal Am. J. Cardiol. Section Abstract Doc Link 10078538 Disease Relevance 0.17 Pain Relevance 0
Drug interaction studies have shown that concomitant administration of sildenafil and nitrates is associated with known sildenafil adverse drug reactions (mainly class effects associated with PDE5 inhibition) and consistent reductions in blood pressure (18).
Negative_regulation (inhibition) of PDE5 in blood associated with adverse drug reaction
20) Confidence 0.58 Published 2010 Journal International Journal of Clinical Practice Section Body Doc Link PMC2810448 Disease Relevance 0.63 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox